X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/gedeon-richter-cariprazine-has-a-real-chance-of-becoming-the-best-selling-atypical-antipsychotic-drug-302111847.html
https://www.fiercepharma.com/marketing/new-depression-label-hand-abbvie-gives-vraylar-ad-campaign-lift-new-focus
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213982
https://www.fiercepharma.com/pharma/abbvies-vraylar-scores-approval-major-depressive-disorder-adds-another-entry-hot-market
https://www.prnewswire.com/news-releases/us-fda-approves-vraylar-cariprazine-as-an-adjunctive-treatment-for-major-depressive-disorder-301705552.html
https://www.prnewswire.com/news-releases/gedeon-richter-the-incidence-of-side-effects-decreased-over-time-with-cariprazine-301650885.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213984
https://www.prnewswire.com/news-releases/abbvie-submits-supplemental-new-drug-application-to-us-fda-for-cariprazine-vraylar-for-the-adjunctive-treatment-of-major-depressive-disorder-301486927.html
https://www.expresspharma.in/zydus-cadila-receives-tentative-approval-from-us-fda-for-cariprazine-capsule/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213948
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213984
https://www.prnewswire.com/news-releases/gedeon-richter-cariprazine-is-well-tolerated-in-the-early-stage-of-schizophrenia-and-has-a-positive-effect-on-engagement-compared-to-another-antipsychotic-301266936.html
https://www.prnewswire.com/news-releases/cariprazine-significantly-improved-negative-symptoms-of-schizophrenia-based-on-real-life-data-from-a-new-observational-study-by-gedeon-richter-plc-301089116.html
https://www.fiercepharma.com/pharma/could-abbvie-allergan-lean-skyrocketing-vraylar-scripts-a-post-humira-world
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-vraylar-204370-cariprazine-capsules-15-mg-3-mg-45-mg-and-6-mg-1573107246.pdf
https://www.fiercepharma.com/marketing/allergan-debuts-new-vraylar-ad-campaign-expanded-indication-for-bipolar-depression
https://in.reuters.com/article/us-iti-study/intra-cellular-drug-fails-bipolar-depression-study-shares-fall-14-idINKCN1U31C4?feedType=RSS&feedName=health
https://www.fiercepharma.com/pharma/allergan-puts-vraylar-blockbuster-track-new-depression-nod
https://www.reuters.com/article/us-allergan-fda/allergans-vraylar-wins-fda-approval-for-bipolar-depression-idUSKCN1SY1V8
http://www.pharmatimes.com/news/fda_accepts_allergans_vraylar_for_review_1253779
https://www.prnewswire.com/news-releases/allergan-announces-fda-acceptance-of-supplemental-new-drug-application-for-vraylar-cariprazine-300719041.html
https://www.fiercepharma.com/marketing/allergan-first-push-for-vraylar-uses-house-cards-to-symbolize-manic-side-bipolar-disorder
https://www.biopharmadive.com/news/allergan-notches-third-trial-success-for-depression-drug/520554/
https://endpts.com/allergan-richter-prep-for-fda-ok-with-positive-phiii-for-cariprazine-in-bipolar-depression/
https://www.reuters.com/article/us-allergan-study/allergan-richters-bipolar-depression-drug-succeeds-in-key-trial-idUSKBN1EC1NA?feedType=RSS&feedName=healthNews
http://www.pharmatimes.com/news/allergan_to_file_cariprazine_for_major_depressive_episodes_1214731
https://endpts.com/allergan-caps-a-bad-day-with-news-the-fda-has-kicked-back-a-supplemental-application-for-cariprazine/
https://endpts.com/allergan-caps-a-bad-day-with-news-the-fda-has-kicked-back-a-supplemental-application-for-cariprazine/
http://www.prnewswire.com/news-releases/allergan-receives-refusal-to-file-letter-from-fda-for-vraylar-cariprazine-supplemental-new-drug-application-snda-for-the-treatment-of-negative-symptoms-in-schizophrenia-300524547.html
https://www.pharmacompass.com/pdf/news/gedeon-richters-reagila-cariprazine-receives-approval-in-europe-1505804752.pdf
http://www.pharmatimes.com/news/eu_nod_for_gedeons_novel_antipsychotic_reagila_1198831
http://raps.org/Regulatory-Focus/News/2017/05/19/27614/EMA%E2%80%99s-CHMP-Recommends-Approval-for-Five-New-Medicines-Four-New-Biosimilars/?utm_source=Email&utm_medium=Informz&utm_campaign=Informz-Emails
http://www.prnewswire.com/news-releases/fda-accepts-supplemental-new-drug-application-snda-for-vraylar-cariprazine-300420031.html
http://www.fiercepharma.com/marketing/allergan-ceo-2017-should-be-kybella-s-breakout-year
http://www.fiercebiotech.com/biotech/allergan-and-richter-push-ahead-despite-phiii-fail-for-depression-drug
http://www.prnewswire.com/news-releases/allergan-announces-us-availability-of-vraylar-cariprazine-for-treatment-of-bipolar-mania-and-schizophrenia-in-adults-300236858.html
http://www.prnewswire.com/news-releases/allergan-and-gedeon-richter-plc-to-present-data-on-vraylar-cariprazine-at-the-american-college-of-neuropsychopharmacology-acnp-annual-meeting-300188117.html
https://www.pharmacompass.com/pdf/news/forest-labs-vraylar-cariprazine-15-45-mg-approved-in-us-for-schizophrenia-1442662395.pdf
Market Place
Share 
